 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || T-Plex-200-A0201/204-A0201 / TSCan Therap
Trial initiation date, IO biomarker, Pan tumor, Metastases: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov) - Jan 11, 2024
P1, N=100, Recruiting, Sponsor: TScan Therapeutics, Inc.
Initiation date: Nov 2023 --> Feb 2024
- ||| T-Plex-200-A0201/204-A0201 / TSCan Therap
Enrollment open, IO biomarker, Pan tumor, Metastases: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 30, 2023
P1, N=100, Recruiting, Sponsor: TScan Therapeutics, Inc.
Initiation date: Nov 2023 --> Feb 2024 Not yet recruiting --> Recruiting
- TSC-200-A0201 / TSCan Therap, T-plex / TSCan Therap
Non-clinical development of T-Plex component TSC-200-A0201: a natural HPV16 E7-specific TCR-T cell therapy for the treatment of HPV16-positive solid tumors (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_728;
Conclusions TSC-200-A0201 exhibits high specificity and potency. Based on these results, TSC-200-A0201 has been cleared by the U. S. FDA for clinical development and has been incorporated in the T-Plex Phase 1 clinical trial master protocol.
- ||| T-Plex-200-A0201/204-A0201 / TSCan Therap
New P1 trial, IO biomarker, Pan tumor, Metastases: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov) - Aug 3, 2023
P1, N=100, Not yet recruiting, Sponsor: TScan Therapeutics, Inc.
- TSC-200-A02 / TSCan Therap
Discovery of TSC-200-A02: A Natural HPV16 E7-Specific TCR-T Cell Therapy Candidate for the Treatment of HPV-Positive Solid Tumors (Poster Board Number: M-198; Hall D) - Apr 20, 2022 - Abstract #ASGCT2022ASGCT_679;
We have advanced the resulting autologous TCR-T cell therapy candidate, TSC-200-A02, to IND-enabling studies. These results validate the use of ReceptorScan, in conjunction with SafetyScan, as a way to rapidly identify naturally occurring, high affinity TCRs that are suitable for clinical development.